Hansa Biopharma Ab
Clinical trials sponsored by Hansa Biopharma Ab, explained in plain language.
-
Breakthrough drug may give hope to kidney patients rejected for transplant
Disease control CompletedThis study tested a drug called imlifidase in 113 highly sensitized kidney patients who had a positive crossmatch against a deceased donor. The drug was given before transplant to reduce the risk of rejection. The main goal was to see how many patients still had a working kidney …
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Breakthrough drug could open door to kidney transplants for 'Impossible' patients
Disease control CompletedThis phase 3 trial tested a drug called imlifidase in 64 highly sensitized kidney transplant patients who had almost no chance of finding a compatible donor. The drug breaks down harmful antibodies, allowing a transplant from a donor that would normally be rejected. The study mea…
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC